SURE-02_An open label, single-arm, phase 2 study of perioperative pembrolizumab plus sacituzumab govitecan, and bladder-saving approach, for patients with muscle-invasive bladder cancer who cannot receive or refuse cisplatin-based chemotherapy

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514569-20-00

Acronym

SURE-02

Enrollment

Registered

2024-10-28

Start date

2022-09-15

Completion date

Unknown

Last updated

2025-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

muscle-invasive bladder cancer

Brief summary

clinical CR-rate.

Detailed description

Bladder-intact event-free survival (BI-EFS);, Pathological response-rate., Safety (CTCAE v-5.0), Overall survival (OS).

Interventions

DRUGKEYTRUDA 25 mg/mL concentrate for solution for infusion

DRUGTrodelvy 200 mg powder for concentrate for solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
clinical CR-rate.	—

Secondary

Measure	Time frame
Bladder-intact event-free survival (BI-EFS);, Pathological response-rate., Safety (CTCAE v-5.0), Overall survival (OS).	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026